What is the significance of the new EOPYY oncology testing coverage?
The expansion of EOPYY oncology testing coverage represents a vital shift toward precision medicine for cancer patients in Greece. Biomarkers are biological indicators that allow doctors to identify the specific molecular characteristics of a tumor, which in turn dictates the most effective treatment strategy. By covering these tests, the National Organization for the Provision of Health Services (EOPYY) enables clinicians to move away from a "one-size-fits-all" approach and toward targeted therapies that increase survival rates and reduce unnecessary side effects.
The recent decision by the Ministry of Health serves as a second amendment to the existing framework for prescribing and reimbursing oncological medications. This amendment specifically updates the list of reimbursable biomarkers and their corresponding clinical indications. For patients, this means that the diagnostic tools required to confirm whether a specific drug will work for their particular pathology are now covered by the state, reducing the financial burden that previously forced many to pay out-of-pocket.
The evolution of the reimbursement decision
The implementation of this coverage has not been without significant delays. Although an initial decision was published in the Government Gazette in October 2025, technical errors necessitated a full year of corrections before the policy could be effectively applied. This delay meant that for much of 2025 and early 2026, oncology patients had to personally fund these essential molecular tests. The current amendment aims to rectify these previous administrative errors and broaden the scope of available diagnostics.
Which specific biomarkers and cancer types are now covered?
The updated reimbursement list includes a diverse array of molecular tests tailored to various stages and types of cancer. The scale of reimbursement varies significantly depending on the complexity of the method used and the specific biomarker being identified.
According to the Ministry of Health's updated decision, the following tests and reimbursement rates are now in effect:
- BRCA1/2: Reimbursed at 400 euros, these tests are critical for high-risk early-stage breast cancer, metastatic prostate cancer (mCRPC), and metastatic pancreatic cancer.
- HRD (Homologous Recombination Deficiency): This advanced test for advanced ovarian cancer receives the highest reimbursement at 870 euros.
- NTRK 1/2/3: Covering various solid tumors—including colorectal, lung, melanoma, thyroid, and sarcomas—these tests are reimbursed at 200 euros.
- MET Exon 14: Aimed at non-small cell lung cancer (NSCLC) across all disease stages, with reimbursement between 200 and 400 euros.
- PIK3CA: Specifically for metastatic breast cancer, provided at a rate of 200 euros.
- PD-L1: Reimbursed at 200 euros for a wide spectrum of tumors, such as NSCLC, triple-negative breast cancer, melanoma, urothelial, head and neck, esophageal, cervical, and stomach cancers.
- Other targeted tests: These include EGFR and RET (200 euros), FGFR (220 euros), EGFR ctDNA (235 euros), and ROS1 (80-240 euros), primarily focusing on lung cancer and metastatic urothelial carcinoma.
What are the potential barriers to accessing these tests?
Despite the expanded coverage, significant systemic hurdles remain regarding patient access to these essential diagnostics. The primary concern is not just the financial reimbursement, but the physical availability of laboratory services and the capacity of the healthcare system to manage the increased demand.
A major bottleneck identified is the availability of appointments at the specific laboratories that have entered into contracts with EOPYY. Even if a test is fully reimbursed, a patient cannot benefit from the precision medicine benefits if they cannot secure a timely appointment. In oncology, where treatment timelines are often measured in days or weeks, delays in diagnostic testing can have severe clinical consequences.
Budgetary constraints and appointment limits
The issue is further complicated by the way EOPYY manages its finances. The organization operates under a closed budget for diagnostic testing, which includes specific spending limits for biomarkers. Because there has been no additional dedicated funding allocated to EOPYY specifically to cover this expansion, there is a risk that the system will hit its spending ceiling quickly. This could lead to a restricted number of available appointments, effectively creating a waiting list for patients who need urgent molecular profiling to begin their treatment.
How does this impact the financial landscape for cancer patients?
The expansion provides substantial financial relief to patients, but it does not entirely eliminate the economic challenges associated with a cancer diagnosis. For many, the ability to have tests like BRCA1/2 or HRD covered by the state represents a saving of hundreds, or even nearly a thousand, euros per diagnostic cycle.
Previously, the errors in the 2025 decision meant that patients were often left to navigate the high costs of molecular testing independently. By correcting these errors and increasing the reimbursement amounts for certain tests, the Ministry of Health is attempting to ensure that the choice of treatment is dictated by medical necessity rather than the patient's ability to pay. However, the lack of a dedicated increase in the EOPYY budget suggests that while the *cost per test* is covered, the *total volume* of tests may remain a point of contention between healthcare providers and the state.
Frequently asked questions
Which cancer types benefit most from the new EOPYY decision?
Lung cancer patients see the widest benefit, as several tests like EGFR, RET, ROS1, and MET Exon 14 are specifically indicated for them. Breast and ovarian cancer patients also benefit significantly through the coverage of BRCA1/2, PIK3CA, and HRD testing.
Why was there a delay in implementing these tests?
The implementation was delayed by approximately one year due to administrative errors in the initial October 2025 decision. These errors required a period of correction and negotiations that had been ongoing since 2024 before the second, corrected amendment could be issued.
Will these tests be available immediately at all laboratories?
Availability is not guaranteed immediately. While the tests are reimbursed, access depends on the availability of appointments at laboratories contracted with EOPYY. Furthermore, EOPYY's closed budget and specific spending limits for biomarkers may restrict the total number of appointments available.
How much does EOPYY reimburse for a BRCA1/2 test?
EOPYY reimburses 400 euros for BRCA1/2 testing. This coverage applies to high-risk early-stage breast cancer, metastatic prostate cancer, and metastatic pancreatic cancer, helping to identify the most appropriate targeted therapy for these conditions.
Is there a limit to how many tests can be covered?
Yes, EOPYY maintains a closed budget for diagnostic testing and sets individual spending limits for biomarkers. Without additional funding, there is a risk that the number of covered tests could be limited once the allocated budget for these specific diagnostics is exhausted.
Key takeaways
- EOPYY has expanded coverage for critical oncology biomarkers to support precision medicine.
- Reimbursement amounts range from 80 euros for ROS1 to 870 euros for HRD testing.
- The expansion covers diverse cancers, including lung, breast, ovarian, and prostate.
- Systemic risks include laboratory appointment availability and EOPYY's closed budget limits.
The future of precision oncology in Greece
The expansion of biomarker coverage marks a significant step toward modernizing cancer care in Greece. By integrating molecular diagnostics into the standard reimbursement framework, the healthcare system is better equipped to provide targeted, effective treatments. However, the success of this policy will ultimately be measured by accessibility. For the clinical benefits of precision medicine to reach the patient, the state must address the logistical challenges of laboratory capacity and ensure that budgetary constraints do not create new barriers to care. The transition from financial coverage to actual clinical access remains the most critical hurdle for the coming year.
